Brødkrumme Forside Iconic Therapeutics Iconic Therapeutics Iconic Therapeutics targets Tissue Factor (TF) in angiogenesis, inflammation, cell growth and metastasis to treat ophthalmologic, oncologic, and autoimmune diseases. Is in Phase II clinical trials in wet-AMD. Iconic Therapeutics' website Lundbeckfonden BioCapital Investeringsår 2014 Lokation San Francisco, California, USA